Mantoux Test Explained: Normal Range, Positive Result Meaning, TB Diagnosis & What to Do (India 2026) | मंटोक्स टेस्ट गाइड
Mantoux Test Explained: Normal Range, Positive Result Meaning, TB Diagnosis & What to Do (India 2026)
मंटोक्स टेस्ट गाइड: Normal Range, Induration कैसे मापें, Positive का मतलब, BCG Vaccine Effect, IGRA से अंतर — पूरी जानकारी
Your child's school has conducted a Mantoux test as part of a TB contact tracing programme, or your doctor has ordered a Mantoux test because you have been in contact with a confirmed TB patient, or you are applying for a visa to a country that requires TB screening. The Mantoux test (also called the Tuberculin Skin Test or TST, or PPD test — Purified Protein Derivative) is the most widely available and historically most used TB screening test in India. But it is also one of the most frequently misread — many patients are told they are "Mantoux positive" and immediately panic about having tuberculosis, when the result requires careful contextual interpretation. A positive Mantoux test does not mean you have active tuberculosis. In India, where BCG vaccination is universal at birth and TB exposure rates are extremely high, a positive Mantoux test most commonly reflects BCG vaccination or past TB exposure — not active TB disease. This guide explains exactly how the Mantoux test works, how to correctly read the result (measuring induration, not redness), what different induration sizes mean in different people, and when a positive result requires further investigation with chest X-ray, sputum, or IGRA (Interferon Gamma Release Assay).
For the more specific modern TB blood test, see our GeneXpert (CBNAAT) guide. For reading lab reports generally, see our beginner's guide to blood test reports.
Child के school में TB contact tracing के लिए Mantoux test हुआ, या confirmed TB patient से contact था, या visa के लिए TB screening required है। Mantoux test (= Tuberculin Skin Test / TST / PPD test) = India में most widely available TB screening test। लेकिन most frequently misread भी। "Mantoux positive" = active TB नहीं। India में BCG vaccination universal + TB exposure rates बहुत high → positive Mantoux = most commonly BCG या past exposure, active TB disease नहीं। यह guide: test कैसे काम करता है, result कैसे correctly read करें (induration measure, redness नहीं), different people में different thresholds, और when chest X-ray/sputum/IGRA ज़रूरी।Table of Contents / विषय सूची
- What Is the Mantoux Test? / Mantoux Test क्या है?
- How It Works — The Immune Mechanism
- The Procedure — Injection, Reading & Measurement
- Reading the Result — Induration vs Redness
- Cut-Off Values by Risk Group — The India Context
- The BCG Vaccine Problem — False Positives in India
- Mantoux vs IGRA (QuantiFERON-TB Gold) — Which to Choose?
- What to Do After a Positive Mantoux / Positive के बाद क्या करें?
- Test Preparation Checklist / टेस्ट की तैयारी
- Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
What Is the Mantoux Test?
The Mantoux test (Tuberculin Skin Test, TST) is a delayed-type hypersensitivity (DTH) skin test used to detect prior sensitisation of the immune system to Mycobacterium tuberculosis antigens. A standardised amount of PPD (Purified Protein Derivative) tuberculin — 5 tuberculin units (5 TU) in 0.1 mL, in India the most common preparation is 1 TU or 2 TU in some settings, but 5 TU is internationally standard — is injected intradermally (just under the skin) on the flexor aspect of the forearm. The result is read at 48–72 hours by measuring the diameter of induration.
Mantoux test (Tuberculin Skin Test, TST) = delayed-type hypersensitivity (DTH) skin test जो Mycobacterium tuberculosis antigens के against immune system की prior sensitisation detect करता है। PPD (Purified Protein Derivative) tuberculin = 5 TU in 0.1 mL — forearm के flexor aspect में intradermally inject। Result 48–72 hours पर induration diameter measure करके read।- PPD contains: A mixture of protein fragments derived from heat-killed Mycobacterium tuberculosis culture — proteins that have been broken down, purified, and standardised. These are non-living, non-infectious fragments that cannot cause TB disease.
- PPD does NOT contain: Live tuberculosis bacteria, DNA or RNA of M. tuberculosis, or any component that can cause tuberculosis infection or replicate.
- Why it produces a reaction only in sensitised individuals: PPD proteins are recognised only by immune systems that have previously been exposed to M. tuberculosis (or closely related mycobacteria — BCG, NTM). People without prior exposure have no T-cells programmed to recognise PPD → no immune reaction → no induration. People with prior exposure have sensitised memory T-cells → these are activated by PPD → migrate to the injection site → cause the induration.
- The test is safe in: HIV-positive patients; pregnant women; children of all ages; elderly patients; immunocompromised patients (though reduced sensitivity). The PPD injection itself cannot cause TB and carries only the tiny risk of localised skin reaction.
How It Works — The Immune Mechanism
The Mantoux test is based on delayed-type hypersensitivity (Type IV hypersensitivity) — a T-cell-mediated immune reaction, not an antibody-mediated reaction. This is a fundamentally different immune mechanism from the IgE-mediated allergy tested by skin prick tests, or the IgG-mediated immunity tested by blood antibody tests. Understanding the T-cell basis of the Mantoux test explains why the result takes 48–72 hours (not minutes, as in IgE allergy) and why it is unaffected by antibiotics.
Mantoux test = delayed-type hypersensitivity (Type IV) — T-cell-mediated immune reaction, antibody-mediated नहीं। IgE allergy (skin prick test — minutes) और IgG antibody tests से fundamentally different। T-cell basis = result 48–72 hours में (minutes नहीं)। Antibiotics से unaffected।When M. tuberculosis bacteria (or BCG vaccine mycobacteria) enter the body, macrophages engulf and process them, presenting TB protein antigens to naïve T-cells in the lymph nodes. This stimulates the naïve T-cells to differentiate into antigen-specific memory CD4+ T helper type 1 (Th1) cells — cells that "remember" the TB antigen and can rapidly respond to it on future encounters. This sensitisation process takes 2–12 weeks after initial TB exposure before the Mantoux test becomes positive — explaining why a Mantoux test done within the first few weeks after TB contact may be falsely negative (the immune system has not yet fully sensitised). Once sensitised, the memory T-cells persist in the body for years to decades.
M. tuberculosis (या BCG) body में enter → macrophages process → TB protein antigens naïve T-cells को present → naïve T-cells = antigen-specific memory CD4+ Th1 cells differentiate। Sensitisation: 2–12 weeks after initial TB exposure। Mantoux 2–12 weeks के अंदर = falsely negative possible (immune system not yet fully sensitised)। Once sensitised: memory T-cells years to decades persist।When PPD is injected intradermally, the PPD proteins are taken up by antigen-presenting cells (APCs — mainly dendritic cells and macrophages) in the skin and presented to any circulating memory T-cells. In a sensitised person: the memory T-cells recognise the PPD proteins as the same TB antigens they were programmed to remember → they activate → migrate to the injection site → produce interferon-gamma (IFN-γ) and TNF-alpha → these cytokines recruit additional macrophages, lymphocytes, and inflammatory cells to the site. The accumulation of these immune cells causes the characteristic induration — a firm, palpable, raised area of skin thickening. The reaction peaks at 48–72 hours — hence the reading time. By 96–120 hours, the reaction begins to subside as the local immune response resolves.
PPD inject → APCs (dendritic cells, macrophages) PPD proteins uptake → memory T-cells को present। Sensitised person में: memory T-cells PPD proteins recognise → activate → injection site migrate → IFN-γ + TNF-alpha produce → macrophages + lymphocytes recruit। Cell accumulation = induration (firm, palpable, raised skin thickening)। Peak 48–72 hours। 96–120 hours: subside।The Procedure — Injection, Reading & Measurement
| Step | Action | Patient Information |
|---|---|---|
| Day 0 (Injection) |
Intradermal injection of 0.1 mL PPD tuberculin on the flexor (inner) surface of the forearm | A trained healthcare worker injects the PPD just under the skin surface — not into a vein or muscle. Correct injection produces a pale, raised "blister-like" wheal of 6–10 mm immediately. If no wheal forms (subcutaneous injection), the test must be repeated on the other arm after 1 week. Mild discomfort, burning, or itching at the injection site is normal. Do not scratch or rub the site. |
| Day 0–2 (Waiting) |
Allow 48–72 hours for the immune reaction to develop | Do not bandage, scratch, or apply any cream, ointment, or medication to the injection site. Do not press or squeeze the site. You may shower normally — water contact does not affect the test. Note: the skin at the injection site may become red, itchy, or slightly swollen within 24 hours — this redness (erythema) is normal and does not represent the test result. Return to the healthcare facility at exactly 48–72 hours for reading. |
| Day 2–3 (Reading) |
Reading and measurement of induration by a trained healthcare worker | The healthcare worker palpates (feels) the injection site with the fingertip to locate the firm, raised area (induration). The transverse diameter (perpendicular to the long axis of the forearm) of the induration is measured in millimetres using a transparent ruler. Redness (erythema) alone is NOT measured — only the hard, palpable raised area. This measurement, in mm, is the Mantoux test result. Reading after 72 hours is still acceptable but may underestimate the true peak induration. |
Reading the Result — Induration vs Redness
- Error 1 — Measuring redness instead of induration (most common): The redness (erythema) can be 30–50 mm while the actual induration is only 5–8 mm. A test report of "Mantoux positive: 25 mm" that is actually measuring redness rather than the firm induration is a false positive. Always ask: "Did the doctor feel the hardness, or just look at the redness?" The induration must be felt — not just seen.
- Error 2 — Reading too early (before 48 hours) or too late (after 120 hours): Reading before 48 hours may underestimate true induration. Reading after 120 hours is unreliable — induration subsides and the test is no longer interpretable. The ideal reading window is 48–72 hours. If the patient cannot come at 48 hours, up to 96 hours is acceptable, but 72 hours is preferred.
- Error 3 — Measuring the longitudinal rather than transverse diameter: The induration should always be measured transversely — perpendicular to the long axis of the forearm. Longitudinal measurement gives a different (typically larger) value and is not the standard measurement.
- Error 4 — Applying the same cut-off to everyone: The cut-off that defines a "positive" Mantoux result varies by the patient's risk group — 5 mm, 10 mm, and 15 mm thresholds are used for different patient populations. Applying 10 mm to an immunocompromised patient (where 5 mm is the appropriate threshold) or to a healthy low-risk adult (where 15 mm may be appropriate in the Indian context) leads to errors in either direction.
Cut-Off Values by Risk Group — The India Context
The "positive" cut-off for the Mantoux test is not a single universal value — it varies based on the patient's individual risk of true TB infection and the probability that a positive result is clinically meaningful rather than a BCG- or NTM-related false positive. Three internationally accepted cut-offs are used:
Mantoux test "positive" cut-off = single universal value नहीं — patient के individual TB infection risk और result clinically meaningful होने की probability पर depend। Three internationally accepted cut-offs use होते हैं।| Induration | Threshold | Patient Groups for Whom This Is "Positive" |
|---|---|---|
| ≥ 5 mm | Positive in HIGH-RISK groups | HIV-positive individuals (any CD4 count — TB is the leading cause of death in HIV); Recent close contacts of confirmed infectious TB cases (particularly sputum AFB smear-positive cases); Patients with fibrotic changes on chest X-ray consistent with old TB; Organ transplant recipients or patients on TNF-alpha blockers (infliximab, adalimumab — these significantly suppress TB immunity); Patients on prednisone equivalent above 15 mg/day for more than 1 month. |
| ≥ 10 mm | Positive in MODERATE-RISK groups | Recent immigrants from high TB prevalence countries (in contexts outside India); Health care workers, laboratory workers, prison staff, and others occupationally exposed to TB; Children below 5 years; Medically high-risk conditions: diabetes mellitus, silicosis, chronic renal failure, haematological malignancies, malnutrition, gastrectomy; Residents and employees of high-risk congregate settings (TB hospitals, homeless shelters, nursing homes). |
| ≥ 15 mm | Positive in LOW-RISK groups | Persons with no known risk factors for TB — healthy, immunocompetent adults with no known TB exposure, no immunosuppression, no occupational risk. In India, this group is large but the threshold of 15 mm is important to avoid over-diagnosing LTBI in BCG-vaccinated individuals with no real risk of progression to active TB. |
- The India challenge — very high TB exposure AND universal BCG vaccination: India is unique in that the population has BOTH an extraordinarily high background rate of true M. tuberculosis exposure (from the world's highest TB burden) AND universal BCG vaccination at birth. This double source of T-cell sensitisation means that a very large proportion of healthy Indian adults will have Mantoux induration of 10–20 mm — from BCG, NTM exposure, or latent TB infection — without any active TB or meaningful risk of progression. Applying a single threshold creates massive over-identification of "positives" who require no clinical intervention.
- What a 10–14 mm Mantoux means in a healthy BCG-vaccinated Indian adult with no TB risk factors: This almost certainly reflects BCG-related tuberculin sensitivity rather than true latent TB infection (LTBI) requiring preventive therapy. No chest X-ray, no sputum, and no preventive isoniazid therapy is indicated on this basis alone. Clinical reassurance is appropriate.
- What a 15 mm+ Mantoux means in a healthy BCG-vaccinated Indian adult with no TB risk factors: May still reflect BCG or NTM — particularly if the BCG was given within the past 10–15 years. Consider IGRA (QuantiFERON-TB Gold) for confirmation — IGRA is not affected by BCG and has higher specificity for true LTBI.
- What a ≥5 mm Mantoux means in a newly HIV-diagnosed patient: Clinically significant — evaluate for both LTBI (with IGRA if available) and rule out active TB by chest X-ray, sputum. Preventive therapy (isoniazid preventive therapy or 3HP) is indicated for LTBI in HIV after active TB is excluded.
The BCG Vaccine Problem — False Positives in India
India has had universal BCG vaccination at birth as part of the national immunisation programme since the 1960s. BCG is a live attenuated (weakened) strain of Mycobacterium bovis — a bovine tuberculosis pathogen closely related to M. tuberculosis. Because BCG shares many antigenic proteins with M. tuberculosis (approximately 2,000 common genes out of BCG's approximately 3,500 genes), BCG vaccination stimulates sensitised memory T-cells that will cross-react with PPD — the mixture of M. tuberculosis proteins used in the Mantoux test. Specifics: the PPD used in the Mantoux test is prepared from M. tuberculosis culture and contains proteins common to both M. tuberculosis AND BCG. When BCG-vaccinated T-cells encounter PPD, they react — producing induration even without any actual TB infection. The magnitude of BCG-related induration: BCG given at birth typically produces induration of 5–15 mm for the first 5–15 years of life. After this, BCG-related reactivity gradually wanes — most adults who were BCG-vaccinated at birth and have had no TB exposure will have less than 10 mm induration after age 30–40. However, BCG given at older ages (after 1 year) or given multiple doses produces more durable and larger BCG-related induration.
BCG false-positive mechanism: BCG = live attenuated M. bovis (M. tuberculosis से closely related, ~2,000 common genes)। BCG sensitised T-cells PPD के साथ cross-react → induration even without TB infection। PPD में M. tuberculosis + BCG दोनों के common proteins। BCG at birth: 5–15 mm induration for first 5–15 years। Gradually wanes after age 30–40 (<10 mm)। Older age BCG या multiple doses: more durable + larger BCG-related induration।Non-tuberculous mycobacteria (NTM — also called environmental mycobacteria or atypical mycobacteria) are mycobacteria found in soil, water, and the environment that are not M. tuberculosis or BCG. Common NTM in India include Mycobacterium avium complex (MAC), M. kansasii, M. fortuitum, M. abscessus, and M. chelonae. NTM are extremely common environmental organisms in India — the warm, humid Indian climate, proximity to water bodies, agricultural work, and soil exposure mean that most Indians encounter NTM repeatedly throughout their lives. Because NTM share some (but not all) antigens with M. tuberculosis, NTM exposure can sensitise T-cells to produce cross-reactive responses to PPD — producing Mantoux induration, typically in the 5–15 mm range. NTM-related Mantoux reactivity generally produces smaller induration than true M. tuberculosis infection — one of the reasons why the 15 mm threshold is more specific for true M. tuberculosis infection even in BCG-vaccinated populations. Like BCG, NTM-related Mantoux positivity is not affected by IGRA — because NTM generally do not produce the ESAT-6 and CFP-10 proteins used as IGRA antigens.
NTM (Non-Tuberculous Mycobacteria): soil, water, environment में। India में common: MAC, M. kansasii, M. fortuitum। Warm/humid Indian climate + agricultural work + soil exposure → most Indians NTM repeatedly encounter। NTM share some M. tuberculosis antigens → T-cells sensitise → PPD cross-reactive response → Mantoux induration (typically 5–15 mm)। NTM-related: generally smaller induration than true M. tuberculosis infection। IGRA negative रहता है (ESAT-6 + CFP-10 = NTM में absent)।Latent Tuberculosis Infection (LTBI) is the condition of harboring viable M. tuberculosis bacteria in the body in an immune-contained, non-replicating state — the bacteria are present but the immune system has successfully contained them, preventing active disease. A person with LTBI has no symptoms, is not infectious, and has a normal chest X-ray — but carries a risk of reactivation to active TB disease if their immunity is significantly impaired. LTBI is diagnosed serologically (by Mantoux or IGRA) — it cannot be confirmed by sputum culture or microbiological tests because there are no bacteria in the airways. Mantoux induration in LTBI: typically 15 mm or more in BCG-vaccinated healthy adults in India — though lower thresholds apply in high-risk groups. The lifetime risk of progression from LTBI to active TB in an immunocompetent person is approximately 5–10% (2–5% in the first 2 years after infection). In an HIV-positive person with LTBI, the risk of reactivation is approximately 5–10% per year — making LTBI identification and preventive therapy essential in HIV patients.
LTBI (Latent TB Infection): viable M. tuberculosis body में, immune-contained, non-replicating। No symptoms, not infectious, normal chest X-ray। Immunity significantly impair → reactivation risk। Serologically diagnose (Mantoux/IGRA) — sputum culture confirm नहीं (airways में bacteria नहीं)। Mantoux in LTBI: typically ≥15 mm in BCG-vaccinated healthy Indian adults (high-risk groups में lower thresholds)। Immunocompetent में lifetime progression risk: 5–10% (first 2 years में 2–5%)। HIV + LTBI: reactivation risk ~5–10%/year → preventive therapy essential।Mantoux vs IGRA (QuantiFERON-TB Gold) — Which to Choose?
| Feature | Mantoux Test (TST) | IGRA (QuantiFERON-TB Gold Plus / T-SPOT.TB) |
|---|---|---|
| Principle | Delayed-type hypersensitivity skin reaction to PPD | Blood test — measures IFN-γ released by T-cells when stimulated with TB-specific antigens (ESAT-6, CFP-10) |
| BCG interference | Yes — significant false positives from BCG vaccination (major limitation in India) | No — ESAT-6 and CFP-10 are absent from BCG. IGRA is not affected by BCG vaccination status. |
| Specificity for M. tuberculosis | Lower — cross-reacts with BCG and most NTM | Higher — ESAT-6 and CFP-10 are specific to M. tuberculosis complex (and Mycobacterium kansasii, M. szulgai — less common) |
| Patient visits | Two visits required (injection + reading 48–72 hours later) | Single blood draw — no return visit needed |
| Cost in India | Very low (₹50–200) — available at government hospitals | Moderate-high (₹2,000–4,500) — primarily at NABL reference labs |
| Reading subjectivity | High — requires trained reader; subject to error (measuring redness vs induration) | Low — laboratory-based, automated measurement, standardised result |
| In immunocompromised | Anergy possible (false negative) — severely immunosuppressed may not mount skin reaction | Also reduced in severe immunosuppression — but has an internal control (mitogen) that detects anergy |
| WHO/NTEP recommendation in India | Still first-line for TB screening (due to cost and availability) — particularly in children | Preferred when: BCG vaccination recent; travel/visa screening; equivocal Mantoux; immunocompromised; clinical decision depends on result precision |
What to Do After a Positive Mantoux / Positive के बाद क्या करें?
Before any diagnosis of latent TB infection (LTBI) can be made, active TB disease must be excluded. A positive Mantoux does not distinguish LTBI from active TB — both produce a positive skin test. Active TB must be evaluated with:
- Chest X-ray (PA view): The primary imaging investigation. Active pulmonary TB shows: cavitation (air-filled holes in the lung — typically in the upper lobes), consolidation, infiltrates, hilar lymphadenopathy, pleural effusion. Old/healed TB shows: fibrotic scars, calcified nodules, calcified hilar lymph nodes — these are not active disease.
- Symptom assessment: Cough for more than 2 weeks, fever (particularly evening fever), night sweats, haemoptysis (blood in sputum), and unexplained weight loss are the cardinal symptoms of active pulmonary TB. Any of these symptoms with a positive Mantoux warrants sputum testing.
- Sputum examination: If symptoms or chest X-ray suggest active TB — three sputum samples (2 on consecutive days, first early morning) for Acid-Fast Bacilli (AFB) smear, GeneXpert/CBNAAT, and mycobacterial culture.
- Only if active TB is excluded can the diagnosis of LTBI be considered and preventive therapy discussed.
When the Mantoux result is positive but the clinical significance is uncertain — particularly in BCG-vaccinated individuals with moderate induration (10–19 mm), no active disease symptoms, and no clear TB risk factors — IGRA (QuantiFERON-TB Gold Plus) can be used to confirm or refute true LTBI:
- Mantoux positive + IGRA positive: True LTBI is highly likely — discuss preventive therapy with a physician.
- Mantoux positive + IGRA negative: The Mantoux positivity most likely reflects BCG vaccination or NTM exposure, not true LTBI. No preventive therapy indicated in a low-risk individual with no symptoms and normal chest X-ray.
- Mantoux positive + IGRA indeterminate: Repeat IGRA, review immunosuppression status, or consult a pulmonologist or TB specialist.
- IGRA is particularly valuable for: travel and visa medical clearance (where BCG-related false positives cause significant unnecessary anxiety and follow-up); healthcare worker TB screening programmes; immigrants from TB-endemic countries; contact investigation around a source case.
If LTBI is confirmed (positive Mantoux or IGRA, active TB excluded by clinical assessment and chest X-ray) in a person at risk of TB reactivation, preventive therapy is offered. The current TB preventive therapy (TPT) regimens used in India (as per NTEP guidelines) include:
- 6H — Isoniazid (INH) 300 mg/day for 6 months: The longest-used TPT regimen. Effective but requires 6 months of daily adherence. Risk of INH-induced liver toxicity (monitor LFTs, particularly if pre-existing liver disease or alcohol use).
- 3HP — Isoniazid 900 mg + Rifapentine 900 mg weekly for 12 doses (3 months): A shorter regimen now recommended by WHO and increasingly adopted by India's NTEP. Fewer doses, better adherence, similar efficacy. Rifapentine is not universally available at all government hospitals in India.
- Absolute priority groups for TPT in India (per NTEP): HIV-positive individuals with confirmed LTBI (after ruling out active TB); household contacts of pulmonary TB patients; children below 5 years of age who are household contacts of TB cases; individuals who are severely immunocompromised (organ transplant, anti-TNF therapy, high-dose steroids).
- Monitoring during TPT: LFT baseline and monthly (particularly during the first 3 months of INH — hepatotoxicity risk); symptom monitoring for peripheral neuropathy (supplement pyridoxine/B6 with INH). Stop TPT immediately if hepatitis symptoms develop (nausea, vomiting, jaundice, abdominal pain).
Test Preparation Checklist / टेस्ट की तैयारी
-
No fasting required before the Mantoux test injection. PPD tuberculin injection is not affected by food or drink intake. The test requires no specific physical preparation. However, inform the administering healthcare worker of all current medications — particularly corticosteroids (prednisone, dexamethasone) and other immunosuppressants, which can suppress the Mantoux reaction and produce false-negative results.
Mantoux test injection से पहले fasting required नहीं। PPD food/drink से affect नहीं। Current medications inform करें — especially corticosteroids (prednisone, dexamethasone) और immunosuppressants → Mantoux reaction suppress → false-negative। -
Inform the healthcare worker of your complete BCG vaccination history and any previous Mantoux or IGRA test results. If you were BCG-vaccinated (virtually all Indians born after 1960), this is critically important for interpreting the result — particularly if the induration is in the 5–15 mm range. Previous positive Mantoux results (documented in the past) also affect interpretation — a "booster effect" (second Mantoux done within 1–3 weeks of the first) can falsely amplify the second result.
BCG vaccination history + previous Mantoux/IGRA results inform करें। BCG-vaccinated (virtually all Indians born after 1960) — especially 5–15 mm range interpretation के लिए critical। Previous positive Mantoux + "booster effect" (second Mantoux within 1–3 weeks) = falsely amplified second result। -
Return at exactly 48–72 hours for the reading appointment — do not miss this window. The Mantoux result must be read between 48 and 72 hours after injection. Reading too early (less than 48 hours) underestimates peak induration. Reading too late (after 96–120 hours) is unreliable as the induration begins to subside. If you cannot attend at 48 hours, the 72-hour reading is preferred; up to 96 hours is the absolute maximum. If you miss the reading window, the test must be repeated.
Reading appointment: exactly 48–72 hours पर return करें। <48 hours: underestimate। >96–120 hours: unreliable (induration subside)। 72 hours preferred; 96 hours absolute maximum। Reading window miss = test repeat। -
Do not scratch, rub, bandage, or apply any substance to the injection site between injection and reading. Scratching disrupts the developing induration and may alter the measurement. Topical steroids applied to the site could suppress the reaction. Water contact (showering) is acceptable and does not affect the test. Note the appearance of the injection site at 24 and 48 hours — mild redness is normal and not the result. Document whether any induration (hardness) is developing before the reading appointment so you can report it to the healthcare worker.
Injection site: scratch, rub, bandage, topical substance नहीं। Topical steroids suppress कर सकते हैं। Shower = acceptable। Injection site 24 और 48 hours पर observe करें — mild redness = normal, result नहीं। Induration (hardness) developing है? Reading appointment पर healthcare worker को report करें। -
If the Mantoux test is being done for visa or employment purposes, ensure the reading is done and documented by a certified physician or immigration-approved healthcare provider. For travel visas to countries requiring TB screening (USA, UK, Canada, Australia, New Zealand, Schengen zone), the Mantoux test must be administered and read by an immigration-approved panel physician — results from other healthcare providers may not be accepted. Check your destination country's specific TB screening requirements before booking the test.
Visa/employment purpose Mantoux: certified physician या immigration-approved healthcare provider से करवाएं। USA, UK, Canada, Australia, NZ, Schengen: immigration-approved panel physician required। Destination country की specific TB screening requirements पहले check करें।
✅ Book Mantoux / TB Screening Tests — NABL Labs
Book the Mantoux test (TST) or the IGRA (QuantiFERON-TB Gold Plus) blood test for TB screening. Also available: ESR, CBC, and complete TB panel. NABL-accredited labs. Digital reports. The Mantoux test requires two visits — injection on Day 0, reading at 48–72 hours. Always pair a positive Mantoux result with chest X-ray review:
Affiliate link: I may earn a small commission at no extra cost to you. Mantoux testing is available free of charge at all government TB clinics, district TB centres, and government hospitals in India. IGRA testing is available at major NABL reference labs. A positive Mantoux test must always be evaluated by a qualified physician (pulmonologist, infectious disease specialist, or MBBS doctor trained in TB management) alongside chest X-ray, clinical history, BCG vaccination status, and TB risk factors. Never self-diagnose or self-treat based on a Mantoux test result.
Mantoux: government TB clinics + district TB centres में free। IGRA: major NABL reference labs। Positive Mantoux: physician से chest X-ray + clinical history + BCG status + risk factors के साथ evaluate। Self-diagnose या self-treat नहीं।TB Screening & Monitoring Support
Two products relevant to TB screening and respiratory illness monitoring — a no-touch infrared thermometer (fever is a cardinal symptom of active TB — persistent low-grade evening fever, night sweats, and unexplained weight loss are the classic TB symptom triad; accurate home temperature monitoring allows early identification of fever patterns that should prompt TB evaluation) and a digital weighing scale (unintentional weight loss is the third cardinal TB symptom — tracking weekly weight accurately is one of the most important self-monitoring tools for any patient being evaluated for TB or on TB treatment, where treatment response is partly assessed by weight gain). These products support symptom monitoring and treatment tracking — they are not treatments for tuberculosis. TB diagnosis requires sputum testing (GeneXpert, AFB smear, culture) and chest X-ray. TB treatment (DOTS regimen) requires physician prescription and government DOTS centre monitoring under India's National TB Elimination Programme (NTEP).
Fever monitoring is a critically important self-monitoring tool for patients with suspected or confirmed TB, for household contacts of TB patients, and for anyone with persistent respiratory symptoms undergoing TB evaluation. The classic TB fever pattern is characteristically different from most other infections: low-grade fever (37.5°C–38.5°C, rather than the high fever of bacterial pneumonia or influenza), predominantly in the late afternoon and evening (hence the term "evening fever" or "vespertine fever"), and accompanied by drenching night sweats that force the patient to change their clothing and bedding. This evening fever pattern — persisting for more than 2 weeks with productive cough and progressive weight loss — is the cardinal symptom complex that should prompt urgent TB evaluation in any Indian patient. Accurate, reproducible temperature measurement at consistent times (early morning baseline, afternoon, and late evening) allows the fever pattern to be documented and presented to the physician. A no-touch infrared thermometer is particularly valuable in households with an index TB case where multiple family members need daily temperature monitoring — eliminating the cross-contamination risk of sharing a contact thermometer between potentially infected and uninfected family members. The Viproud thermometer's one-second measurement and no-touch design make it practical for monitoring children and elderly family members who may not cooperate well with axillary or oral thermometers. Temperature monitoring does not diagnose TB. Any fever persisting for more than 2 weeks, particularly with cough, night sweats, or weight loss, requires medical evaluation. Do not use a thermometer result to substitute for physician assessment or to delay seeking medical care.
Fever monitoring: TB evaluation + household contacts + respiratory symptoms में critically important। Classic TB fever pattern: low-grade (37.5–38.5°C), late afternoon/evening ("evening fever" / "vespertine fever"), drenching night sweats। >2 weeks + productive cough + progressive weight loss = urgent TB evaluation। Accurate temperature: consistent times (morning baseline, afternoon, evening) — pattern document + physician को present। No-touch: household index TB case — multiple family members daily monitoring। Cross-contamination risk eliminate (shared contact thermometer से)। Viproud: 1 second, no-touch — children + elderly cooperative नहीं। Fever monitoring = TB diagnose नहीं। 2 weeks+ fever + cough/night sweats/weight loss → medical evaluation। View on Amazon IndiaAffiliate link — small commission at no extra cost.
Unexplained, progressive weight loss is one of the three cardinal symptoms of active pulmonary tuberculosis — alongside cough of more than two weeks duration and evening fever with night sweats. TB causes significant weight loss through multiple mechanisms: the chronic inflammatory state (elevated TNF-alpha and other cytokines from the immune response) causes profound anorexia (loss of appetite) and accelerated metabolic catabolism; malabsorption from intestinal TB or severe pulmonary TB may contribute; and the caloric cost of the immune battle against the mycobacteria is substantial. Typical TB-related weight loss: 5–15 kg over several months, often occurring so gradually that the patient attributes it to "stress" or "diet change" without recognising it as a disease symptom. Accurate, documented weekly weight measurement provides two essential clinical functions. First, as a diagnostic clue: if a patient with persistent cough is also losing 0.5–1 kg per week consistently, this significantly strengthens the clinical suspicion for TB and urgently prioritises investigation. Second, as a treatment response marker: once TB treatment (the RNTCP/NTEP DOTS regimen — typically 2 months of HRZE followed by 4 months of HR) is initiated, weight gain is one of the most reliable and patient-visible markers of treatment response. Most TB patients begin to gain weight within the first 2–4 weeks of effective treatment as appetite returns and the inflammatory state subsides. A patient who is on TB treatment and not gaining weight — or continuing to lose weight — warrants urgent review for drug resistance, poor adherence, or co-morbidities. Weekly weight documentation, presented to the DOTS supervisor or treating physician, directly contributes to treatment monitoring. A weighing scale is a monitoring tool — it does not diagnose TB. A doctor must evaluate unexplained weight loss with clinical examination, chest X-ray, and sputum testing.
Unexplained progressive weight loss = TB के three cardinal symptoms में से एक। TB weight loss mechanisms: TNF-alpha + cytokines → anorexia + metabolic catabolism। Intestinal TB में malabsorption। Typical: 5–15 kg over months। Gradual → "stress" या "diet change" attribute। Weekly weight: Two functions। 1. Diagnostic clue: 0.5–1 kg/week loss + persistent cough = TB suspicion strengthen, investigation prioritise। 2. Treatment response marker: DOTS regimen (2 months HRZE + 4 months HR) → weight gain = treatment response। 2–4 weeks में weight gain शुरू। Treatment पर weight not gaining/losing = urgent review (drug resistance, poor adherence, co-morbidities)। DOTS supervisor/physician को weekly weight present। Monitoring tool — TB diagnose नहीं। View on Amazon IndiaAffiliate link — small commission at no extra cost.
Related Tests / संबंधित जांचें
These tests are commonly ordered alongside or after the Mantoux test for complete TB evaluation:
Mantoux test के साथ या बाद में ये जांचें complete TB evaluation में order होती हैं:Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
Not necessarily — a 12 mm Mantoux induration requires careful contextual interpretation. In India, where virtually every adult has been BCG-vaccinated at birth and where TB exposure rates are extremely high, a 12 mm induration is in the range that could reflect BCG vaccination, exposure to environmental non-tuberculous mycobacteria (NTM), latent TB infection (LTBI), or — in the absence of symptoms and normal chest X-ray — is most commonly from BCG or NTM rather than true active disease. Whether 12 mm is "positive" depends on your risk category: in an HIV-positive patient, a healthcare worker, or a close household contact of an active TB case, 10 mm is the standard positive cut-off (so 12 mm would be considered positive). In a healthy adult with no TB risk factors, some guidelines use 15 mm as the cut-off, making 12 mm in this group more likely to reflect BCG or NTM. The most important next steps: a chest X-ray to rule out active pulmonary TB (if your chest X-ray is normal and you have no TB symptoms, your risk is much lower); and if you are in a high-risk group, an IGRA (QuantiFERON-TB Gold) test to distinguish true LTBI from BCG-related false positivity. Never interpret a Mantoux result in isolation — always with a physician who knows your full clinical history.
उत्तर: Necessarily नहीं। 12 mm India में: BCG vaccination, NTM exposure, या LTBI — active disease most commonly नहीं (no symptoms + normal CXR)। "Positive" = risk category dependent: HIV/healthcare worker/household contact में ≥10 mm positive (12 mm = positive)। Healthy adult no risk factors में: some guidelines 15 mm cut-off (12 mm = BCG/NTM more likely)। Next steps: Chest X-ray (normal + no symptoms = much lower risk)। High-risk group: IGRA (true LTBI vs BCG false positivity)। Physician के साथ full clinical history के साथ interpret।Yes — but interpretation is significantly more complex and the specificity is lower in BCG-vaccinated individuals. BCG vaccination at birth (as given to virtually all Indians) stimulates T-cells that cross-react with PPD, producing Mantoux induration of 5–15 mm for the first 5–15 years — sometimes longer. As an adult (above 25–30 years), BCG-related Mantoux reactivity typically wanes and most people who were BCG-vaccinated at birth and have had no TB exposure will have less than 10 mm induration. However, this is not universal. A very large induration (20 mm or more) in a BCG-vaccinated adult is more likely to reflect true TB exposure or LTBI than BCG alone. A moderate induration (10–19 mm) in a BCG-vaccinated adult without TB risk factors is less likely to be clinically meaningful — IGRA testing provides more specific information in this situation. The key principle: in BCG-vaccinated individuals, Mantoux is a sensitive but non-specific test. When clinical decisions depend on whether a person has true LTBI, IGRA (which uses ESAT-6 and CFP-10 antigens absent from BCG) is the preferred confirmatory test.
उत्तर: हाँ — लेकिन interpretation significantly more complex + specificity lower। BCG at birth: T-cells PPD cross-react → 5–15 mm induration for first 5–15 years (sometimes longer)। Adult (>25–30 years): BCG reactivity typically wane (<10 mm in most)। ≥20 mm adult BCG-vaccinated: true TB exposure/LTBI more likely। 10–19 mm BCG-vaccinated adult (no risk factors): clinically meaningful less likely → IGRA more specific। BCG-vaccinated में Mantoux = sensitive but non-specific। Clinical decision LTBI depends: IGRA (ESAT-6/CFP-10 BCG में absent) = preferred confirmatory test।The Mantoux test (TST) and IGRA (Interferon Gamma Release Assay — QuantiFERON-TB Gold Plus, T-SPOT.TB) both detect T-cell-mediated immunity to M. tuberculosis, but they differ in crucial ways. The Mantoux test measures the delayed-type hypersensitivity skin reaction to PPD — a mixture of M. tuberculosis proteins that includes antigens shared with BCG. It requires two visits (injection + reading at 48–72 hours) and is subject to reading errors. It is falsely positive from BCG vaccination and NTM exposure. IGRA is a blood test — a small blood sample is taken, incubated with specific M. tuberculosis antigens (ESAT-6 and CFP-10), and the amount of interferon-gamma released by the patient's T-cells in response is measured. Crucially: ESAT-6 and CFP-10 are present in M. tuberculosis but absent from BCG and from most NTM species — making IGRA highly specific for true M. tuberculosis exposure, unaffected by BCG vaccination. IGRA requires only a single blood draw, has no reading variability, and has an internal control that detects anergy (lack of immune response) in severely immunocompromised patients. The main limitation of IGRA is cost (₹2,000–4,500 vs ₹50–200 for Mantoux) and limited availability at smaller Indian labs. When precision matters (BCG-vaccinated patients, visa screening, healthcare worker screening), IGRA is the preferred test.
उत्तर: Mantoux (TST): DTH skin reaction to PPD (M. tuberculosis + BCG shared antigens)। 2 visits। Reading errors possible। BCG + NTM false positives। IGRA: blood test। ESAT-6 + CFP-10 (M. tuberculosis में present, BCG + most NTM में absent)। T-cells से IFN-γ measure। Single blood draw। No reading variability। Internal control (anergy detect)। BCG-unaffected — highly specific for true M. tuberculosis exposure। Limitation: cost (₹2,000–4,500 vs Mantoux ₹50–200) + limited availability। Precision matters (BCG-vaccinated, visa, healthcare workers): IGRA preferred।For HIV-positive patients, the Mantoux interpretation and clinical response is fundamentally different from that for immunocompetent individuals. In HIV, the cut-off for a positive Mantoux is 5 mm (not 10 or 15 mm) — because HIV suppresses the immune system, reducing the intensity of the delayed hypersensitivity reaction. So even a 5 mm induration in an HIV patient indicates likely M. tuberculosis sensitisation. However, there is an important additional concern: HIV severely impairs T-cell function, so some HIV patients with actual TB exposure may produce little or no induration (anergy) — a false-negative Mantoux. This means both false negatives (from anergy) and true positives at 5 mm threshold need to be considered. If your Mantoux is ≥5 mm as an HIV patient: first, your physician will order a chest X-ray and sputum to actively exclude active TB (because the risk of reactivation from LTBI to active TB in HIV is 5–10% per year — far higher than in immunocompetent individuals). If active TB is excluded, isoniazid preventive therapy (6 months) or 3HP (3 months) is recommended — this is now part of India's NTEP guidelines for HIV patients. Even if the Mantoux is negative (below 5 mm), your HIV physician will likely also offer IGRA testing (which has an internal mitogen control that distinguishes anergy from true TB negativity) before concluding you have no LTBI.
उत्तर: HIV-positive patients में Mantoux interpretation fundamentally different। Cut-off: 5 mm (not 10/15) — HIV immune system suppress → DTH reaction intensity reduce। 5 mm = likely M. tuberculosis sensitisation। Additional concern: HIV = T-cell function severely impair → anergy possible → false-negative Mantoux। ≥5 mm Mantoux in HIV: Chest X-ray + sputum → active TB exclude। Active TB excluded → IPT (6 months) या 3HP (3 months) — NTEP guidelines। Mantoux negative (<5 mm): IGRA testing (mitogen control = anergy vs true TB negativity distinguish) → LTBI conclude नहीं without IGRA।In BCG-vaccinated Indian children (essentially all children born in India after 1960), some degree of Mantoux positivity is very common and expected — particularly within the first 5–10 years of BCG vaccination. A child vaccinated at birth may have induration of 5–15 mm simply from BCG sensitivity, with no TB infection whatsoever. What to expect: if the induration is below 10 mm, this is likely BCG-related in most Indian children with no TB exposure or risk factors — reassurance is appropriate. If the induration is 10–14 mm with no TB symptoms and no known TB contact: school TB screening in India usually requires physician review and a chest X-ray to confirm no active disease, but most of these children will be assessed as healthy with no further action needed. If the induration is 15 mm or more, or if the child has any symptoms (persistent cough, fever, weight loss, fatigue), TB evaluation should be completed urgently. If the child has been in close household contact with a confirmed TB case: even 5 mm is considered positive (high-risk threshold) and warrants full clinical evaluation. Do not panic if your BCG-vaccinated child has a positive Mantoux — take the result to the school's recommended physician, who will assess the full picture including symptoms, chest X-ray, and TB contact history before recommending any further steps.
उत्तर: BCG-vaccinated Indian children में Mantoux positivity very common + expected — especially first 5–10 years post-BCG। 5–15 mm = BCG sensitivity, TB infection नहीं। <10 mm (no symptoms, no TB exposure): BCG-related likely — reassurance appropriate। 10–14 mm (no symptoms, no known TB contact): physician review + chest X-ray → most = healthy, no further action। ≥15 mm या symptoms (persistent cough, fever, weight loss): urgent TB evaluation। Close household contact of confirmed TB case: even 5 mm = positive (high-risk threshold) → full clinical evaluation। Panic नहीं — result physician को दें, symptoms + CXR + TB contact history के साथ assess।- India's National TB Elimination Programme (NTEP) — TB Preventive Therapy Guidelines: Nikshay — NTEP India National TB Programme Portal
- WHO — Latent TB Infection Treatment Guidelines: WHO — Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management
- CDC — Tuberculin Skin Testing: CDC — TB Testing — Tuberculin Skin Test Information
⚠️ Medical Disclaimer / चिकित्सा अस्वीकरण
This article is for educational purposes only. Mantoux test results must be interpreted by a qualified physician or TB specialist alongside BCG vaccination history, TB contact history, clinical symptoms, chest X-ray findings, and immunological status. A positive Mantoux test does not diagnose active TB — it requires further investigation including chest X-ray and sputum testing. A negative Mantoux test does not rule out active TB — particularly in immunocompromised patients (anergy). Never self-diagnose or self-treat TB based on a Mantoux result. TB treatment (DOTS regimen) must be supervised by India's NTEP through government DOTS centres — do not self-purchase TB medications. If you have symptoms consistent with active TB (persistent cough >2 weeks, evening fever, night sweats, haemoptysis, weight loss), seek medical evaluation urgently without waiting for Mantoux test results.
यह लेख केवल शैक्षिक उद्देश्यों के लिए है। Mantoux results को physician से BCG history + TB contact history + symptoms + chest X-ray + immunological status के साथ interpret करवाएं। Positive Mantoux = active TB diagnose नहीं — chest X-ray + sputum ज़रूरी। Negative = active TB rule out नहीं (anergy in immunocompromised)। Self-diagnose या self-treat TB नहीं। TB treatment (DOTS): NTEP + government DOTS centres — self-purchase नहीं। Active TB symptoms (cough >2 weeks, evening fever, night sweats, haemoptysis, weight loss) → Mantoux results wait किए बिना urgent medical evaluation।
Comments
Post a Comment